Mucosis’s lead program SynGEM® seeks to develop a new mucosal vaccines to prevent respiratory syncytial virus vaccine that can be administered to humans by a simple spray in the nose. The program is particularly directed at achieving better protection against RSV in vulnerable people, such as elderly and children. Mucosis also runs research programs aimed at the development of mucosal vaccines to prevent pneumococcal related diseases, and an oral vaccine to prevent bacterial diarrhea (shigella/etec). These programs build upon the success of the Mucosis FluGEM® which achieved proof-of-concept for the Mimopath platform.
The development phases of the Mucosis programs